MENU
+Compare
MNTL
ETF ticker: NASDAQ
AS OF
Jul 16 closing price
Price
$23.21
Change
-$0.19 (-0.81%)
Net Assets
10.09M

MNTL stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
MNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for MNTL with price predictions
Jul 18, 2025

MNTL's RSI Oscillator is remaining in overbought zone for 4 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

MNTL broke above its upper Bollinger Band on July 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 13, 2025. You may want to consider a long position or call options on MNTL as a result. In of 19 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MNTL just turned positive on June 16, 2025. Looking at past instances where MNTL's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .

MNTL moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MNTL crossed bullishly above the 50-day moving average on June 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 32 cases where MNTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Medtronic plc (NYSE:MDT), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Neuroscience and Mental Health ETF ETF is 34.41B. The market cap for tickers in the group ranges from 179.29M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is VYGR at 179.29M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Neuroscience and Mental Health ETF ETF was 2%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was -6%. SLDB experienced the highest price growth at 21%, while SRPT experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Tema Neuroscience and Mental Health ETF ETF was 101%. For the same stocks of the ETF, the average monthly volume growth was 60% and the average quarterly volume growth was 94%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 72
Price Growth Rating: 56
SMR Rating: 77
Profit Risk Rating: 77
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
MNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co